These reports are aggregated from clinical isolates submitted to the UCSF clinical microbiology laboratory from patients at the UCSF Parnassus and Mission Bay campuses and are meant to guide clinicians in selecting empiric therapy. Patient characteristics must be incorporated in determining risks and therapy should be modified based on susceptibility testing results when available. Breakpoints for susceptibility are via CLSI guidelines.
See Adult Antibiogram 2019 in classic Table form (PDF)
16 Organisms
Citrobacter freundii
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
44 | 63 | 98 | 61 | 93 | 84 | 86 | 87 | 95 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
E. coli
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
555 | 69 | 99 | 79 | 78 (91)* | 82 | 61 | 94 | 99 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime ( )* including susceptible dose-dependent isolates, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Enterobacter cloacae
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
123 | 66 | 91 | 66 | 94 (98)* | 94 | 91 | 72 | 99 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *includes susceptible dose-dependent isolates, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Enterococcus faecalis (bloodstream isolates)
Total Isolates | AMP | NAF | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
30 | 100 | N/A | N/A | 23 | N/A | 97 | 100 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid
Enterococcus faecium (bloodstream isolates)
Total Isolates | AMP | NAF | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
23 | 13 | N/A | N/A | 30 | N/A | 39 | 100* | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. AMP-ampicillin, NAF-nafcillin, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin *isolates are susceptible dose-dependent, LZD-linezolid
Klebsiella aerogenes
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
44 | 77 | 95 | 79 | 100 | 100 | 88 | 81 | 97 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Klebsiella oxytoca
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
45 | 84 | 100 | 84 | 91 (98)* | 84 | 84 | 86 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *(including susceptible dose-dependent isolates), CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Klebsiella pneumoniae
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
206 | 77 | 94 | 80 | 80 (90)* | 83 | 82 | 88 | 97 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *including susceptible dose-dependent isolates, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Proteus mirabilis
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
122 | 94 | 100 | 95 | 95 (98)* | 88 | 72 | 99 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime *including susceptible dose-dependent isolates, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Pseudomonas aeruginosa
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
238 | N/A | N/a | 89 | 91 | 97 | 84 | 85 | 89 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Serratia marcescens
Total Isolates | CTRX | ERTA | CTAZ | CFPM | TOB | CIP | P/T | MER |
---|---|---|---|---|---|---|---|---|
51 | 96 | 100 | 100 | 100 | 100 | 98 | 100 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. CTRX-ceftriaxone, CFPM-cefepime, CIP-ciprofloxacin, MER –meropenem, P/T-piperacillin-tazobactam, TOB-tobramycin
Staphylococcus aureus
Total Isolates | PCN | NAF | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
562 | N/A | 73 | 73 | 91 | 95 | 100 | 100 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid
Staphylococcus aureus, MRSA
Total Isolates | PCN | NAF | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
148 | N/A | N/A | 56 | 88 | 90 | 100 | 100 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid
Staphylococcus aureus, MSSA
Total Isolates | PCN | NAF | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
422 | N/A | 100 | 78 | 93 | 97 | 100 | 100 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid
Staphylococcus epidermidis
Total Isolates | PCN | NAF | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
248 | N/A | 38 | 60 | 89 | 51 | 100 | 100 | 100 |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. PCN-penicillin, NAF-nafcillin, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid
Streptococcus pneumoniae
Total Isolates | PCN | CTRX | CLIN | DOX | T/S | VANC | DAP | LZD |
---|---|---|---|---|---|---|---|---|
562 | 100 (72)* | 100 (83)* | 94 | 94 | 94 | 100 | N/T | N/T |
% Strains Susceptible, tested from all sites except as indicated
N/A-testing NOT APPLICABLE to organism. PCN-penicillin *susceptibility based on meningitis breakpoint, CTRX-ceftriaxone *susceptibility based on meningitis breakpoint, CLIN-clindamycin, DOX –doxycycline, T/S-trimethoprim/sulfamethoxazole, VANC-vancomycin, DAP-daptomycin, LZD-linezolid, N/T-not tested